News

In this sturdy, NIAAA is working in partnership with XenoPort, a biopharmaceutical company, which will supply gabapentin enacarbil. Around 346 patients will be enrolled in this randomized, double

The Italian biopharmaceutical firm has also filed an application for orphan designation in the US. RTT primarily affects females with an estimated prevalence ranging from 1:10-20,000 females and

The company said that the study initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon selection.

DPX-Survivac is Immunovaccine’s new T cell activating immunotherapy, while epacadostat (INCB24360) is Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. Under the deal, both the firms will co-fund

Galafold is the first investigational Fabry drug to be granted accelerated assessment in the European Union (EU). In the US, the company plans to carry out a pre-NDA

The new facility will allow the company to complement its current ADC offering with full bio-conjugation services to meet increasing market demand. The investment in clinical and commercial

Under the deal, BioNTech’s subsidiaries, BioNTech RNA Pharmaceuticals and EUFETS, will work with Siemens to build a fully automated and digitalized production site to provide capacity for BioNTech’s

The company presented the results of a clinical trial comparing Flublok Quadrivalent to a traditional egg-based quadrivalent inactivated vaccine. The data demonstrate superior performance of Flublok based on

The new facility in Cambridge, which will be located at 100 Binney Street in Kendall Square, is expected to open in 2018. The ongoing site expansion in the